F3Y.F Microba Life Sciences Limited
- Market cap
- EUR 13.0M
- P/E
- -
- P/B
- 0.86x
- ROE
- -85.0%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Jun 2026.
Is F3Y.F undervalued?
Graham numberThe Graham number of Microba Life Sciences Limited cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Microba Life Sciences Limited fundamental analysis
No fundamental analysis for Microba Life Sciences Limited yet.
Microba Life Sciences Limited stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Microba Life Sciences Limited
Microba Life Sciences Limited provides microbiome testing, supplements, and analysis services in Australia, Europe, New Zealand, the United Arab Emirates, the United Kingdom, the United States, Asia, and Ireland. It operates through, Testing Services and Supplements, and Research and Development segments. The company also develops pathology, therapeutics, and diagnostics services based on the human gut microbiome. In addition, it offers MetaPanel, a metagenomic test for path…
Full company profileMicroba Life Sciences Limited financial statements
Microba Life Sciences Limited annual financial statements (AUD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 4.69M | 5.42M | 12.1M | 15.7M | 14.8M |
| Gross Profit | 2.37M | 2.68M | 5.91M | 7.44M | 7.03M |
| Operating Income | -16.3M | -20.2M | -26.8M | -24.6M | -20.3M |
| EBITDA | -9.91M | -11.0M | -17.1M | -10.5M | -16.4M |
| Net Income | -11.5M | -12.7M | -19.9M | -14.9M | -20.7M |
| EPS | -0.04 | -0.03 | -0.04 | -0.03 | -0.03 |
| Balance Sheet | |||||
| Total Assets | 39.5M | 47.0M | 58.0M | 47.4M | 39.8M |
| Total Liabilities | 5.94M | 8.38M | 16.8M | 14.9M | 15.4M |
| Shareholders' Equity | 33.5M | 38.6M | 41.2M | 32.5M | 24.4M |
| Cash & Short-term Investments | 30.6M | 32.0M | 20.9M | 11.7M | 7.95M |
| Cash Flow | |||||
| Capital Expenditure | 1.87M | 3.04M | 4.38M | 2.90M | 3.91M |
| Free Cash Flow | -12.3M | -15.4M | -19.9M | -14.9M | -16.3M |
| Ratios | |||||
| ROE | -34.2% | -32.9% | -48.4% | -46.0% | -85.0% |
| ROA | -29.1% | -27.0% | -34.4% | -31.5% | -52.1% |
| Net Profit Margin | -244.6% | -233.9% | -164.9% | -95.3% | -140.4% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Microba Life Sciences Limited dividends
Microba Life Sciences Limited has not paid dividends in the last 5 fiscal years.
Who owns Microba Life Sciences Limited
- Insiders 41.97%
- Institutions 24.12%
- Public & others 33.92%
- Shares outstanding 743M
- Free float 269M
Microba Life Sciences Limited company profile
- Company name
- Microba Life Sciences Limited
- Ticker
- F3Y.F
- ISIN
- AU0000209868
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Fiscal year end
- June
- Address
- 324 Queen Street, Brisbane, QLD, Australia, 4000
- Phone
- 61 13 0097 4621
- Website
- microba.com
About Microba Life Sciences Limited
Microba Life Sciences Limited provides microbiome testing, supplements, and analysis services in Australia, Europe, New Zealand, the United Arab Emirates, the United Kingdom, the United States, Asia, and Ireland. It operates through, Testing Services and Supplements, and Research and Development segments. The company also develops pathology, therapeutics, and diagnostics services based on the human gut microbiome. In addition, it offers MetaPanel, a metagenomic test for pathogen detection; microba microbiome explorer; research testing services; and data-driven therapeutics platform that develops therapies for ulcerative colitis, inflammatory bowel autoimmune diseases, oncology, and allergy. Microba Life Sciences Limited was incorporated in 2017 and is based in Brisbane, Australia.
Microba Life Sciences Limited management
6- Mr. James HeathCFO & Company Secretary
- Dr. Luke ReidChief Executive Officer (Leave of Absence)
- Mr. Geoffrey C. CockerillInterim Chief Executive Officer
- Prof. Philip HugenholtzCo-Founder & Chair of Scientific Advisory Board
- Dr. David WoodChief Technology Officer
- Prof. Lutz KrauseChief Scientific Officer